Stock(600222)Hot line:010-61006450


Come and join us in the new era of pharmaceutical industry!

Company Introduction

  • 2005

    Founded in 2005

  • 1000+


  • No.1

    Top 10 Chinese pharmaceutical R & D companies

Leadingpharm was established in 2005 and was listed on the Shanghai Stock Exchange in 2015 (stock code: 600222). It is a high-tech enterprise providing pharmacy preclinical research, clinical CRO and CDMO services to the world. It has been rated as one of the "Top Ten Chinese Pharmaceutical R&D Companies (ranked No. 1 in 2019/2020)" for many years.

From the beginning of its establishment, Leadingpharm took "We make China a world-class player in pharmaceutical technology and production process" as the enterprise vision.Until now, Leadingpharm has built cooperation with over 500 upstream and downstream enterprises. More than 400 pharmaceutical research and development projects and more than 500 clinical research projects have been undertaken, more than 200 patents have been applied for, and nearly 100 patents have been licensed .

Headquartered in Beijing Zhongguancun Hi-tech Park, Leadingpharm has a 10000 square meters research and development laboratory. Six R & D platforms in line with international standards (FDA、EMA and NMPA GMP standards) has been established in Lifezhengzhou, including New Drug Screening and Testing Platform, Drug Evaluation Platform (Animal Room with GLP、AAALAC、CNAS Certification), Macromolecular Pilot and Mass Production Service Platform, Small Molecular CMC Preparation Research and Production Platform, Cell Technology Service Platform and Clinical CRO Platform. The Leadingpharm (Chongqing) Biomedical Integrated R & D Service Base is under construction,Leadingpharm is going to build five plates including Chongqing Branch of Leadingpharm Research Institute, MAH Company (Chongqing) of Leadingpharm, CRO Company of Cell and Gene Therapy, CDMO Base, Chongqing MAH Information Platform and Management Center. Combining Generic Drug and Innovative Drug, driven by imitation and creation, providing customers with pharmaceutical R & D life cycle of diversified services.A joint venture has been set up in Hangzhou to establish the first High-end Preparation Research Institute for pediatric medication in China, create China's largest professional drug research and development platform for children, truly meet the drug demands of front-line pediatricians, solve the problem of drug shortage, and escort the healthy growth of children.